Browse the evidence

Biological aging is driven by the interaction between accumulated cellular damage and the decline of homeostatic resilience mechanisms, rather than chronological time alone.

Focus on maintaining healthspan by understanding that aging is not just a clock ticking but a biological process influenced by damage and repair. While no specific protocol is given, the implication is that interventions targeting the hallmarks of aging (like inflammation, mitochondrial function, or senescence) may slow biological aging.

Cellular senescence and the accumulation of senescent cells contribute to tissue degeneration and age-related diseases, making their removal or suppression a potential therapeutic target.

Understanding senescence highlights the importance of maintaining tissue health and potentially targeting senescent cells in the future. Current research focuses on quantifying senescence burden in humans.

Plasma levels of the adipokine omentin-1 are significantly decreased in obese and overweight individuals compared to lean individuals, and these levels are inversely correlated with BMI, waist circumference, and insulin resistance.

This research identifies omentin-1 as a biomarker that drops as you gain visceral fat and become insulin resistant. While there is no current clinical test for omentin-1, this finding reinforces that reducing visceral fat (through caloric deficit and exercise) is likely to restore healthy adipokine profiles, including omentin-1, which may improve insulin sensitivity.

Liver PPAR-gamma is essential for triglyceride clearance; its absence causes hyperlipidemia and insulin resistance even when hepatic steatosis is reduced.

Do not assume that reducing liver fat automatically improves metabolic health. The liver plays a critical role in clearing triglycerides from the blood. If the mechanism for this clearance (PPAR-gamma) is impaired, reducing liver fat can actually worsen insulin resistance and heart disease risk by forcing lipids into other tissues like muscle and fat.

In the absence of adipose tissue, the liver becomes the primary site of action for thiazolidinediones (TZDs) like rosiglitazone.

For patients with severe lipoatrophy, TZDs like rosiglitazone work by acting on the liver, not fat. If you lack fat tissue, the liver is the key to the drug's effectiveness. In normal individuals, the liver's role in this drug's action is minor compared to fat tissue.

Liver PPAR-gamma protects extra-hepatic tissues from triglyceride accumulation and insulin resistance by facilitating hepatic lipid clearance.

Your liver's ability to clear fats from your blood is critical for your muscle health. If your liver cannot process lipids efficiently (due to low PPAR-gamma activity), those fats accumulate in your muscles, leading to insulin resistance and metabolic disease, even if your liver itself looks healthy.

Aging is characterized by a conserved transcriptional signature across mammals involving the upregulation of inflammatory and immune response genes (e.g., APOD, CTSS) and the downregulation of mitochondrial and collagen-related genes.

This research identifies specific gene expression patterns (increased inflammation/immune activity, decreased mitochondrial/collagen function) that are consistent hallmarks of aging across species. While this paper does not prescribe an intervention, it highlights that aging involves active biological responses (like inflammation) rather than just passive wear-and-tear. Future interventions targeting these specific pathways (e.g., anti-inflammatories or mitochondrial support) may be more effective than generic approaches.

Leptin decreases hypothalamic AMPK activity, whereas ghrelin increases it, indicating that these hormones regulate food intake by modulating AMPK.

Your body uses hormones like leptin (satiety) and ghrelin (hunger) to control the brain's energy sensor (AMPK). Leptin turns this sensor down to stop eating, while ghrelin turns it up to start eating. Understanding this balance helps explain why hormonal imbalances can disrupt hunger cues.

Females in the Asia-Pacific region generally exhibit a higher prevalence of Metabolic Syndrome compared to males, although this varies by specific study and setting.

Women in the Asia-Pacific region face a higher risk of Metabolic Syndrome than men in most studies. This highlights the importance of targeted screening and prevention strategies for women, particularly in urban settings.

The prevalence of Metabolic Syndrome in the Asia-Pacific region is increasing over time (secular trends) in countries like China, South Korea, and Taiwan.

Metabolic Syndrome rates are rising in China, South Korea, and Taiwan. This trend is driven by lifestyle changes, so focusing on diet and exercise is crucial to prevent further increases.

In elderly women, the association between grip strength and mortality is not statistically significant after adjusting for confounding factors and body composition.

For elderly women, grip strength alone may not be a reliable standalone predictor of mortality risk after accounting for other health factors. The predictive power seen in men was not replicated in this female cohort, likely due to sample size.

Obesity prevalence in Europe has reached epidemic proportions, with significant geographic variation showing higher rates in Central, Eastern, and Southern Europe compared to Western and Northern Europe.

Obesity is a widespread and serious medical disorder in Europe, not just a cosmetic issue. Rates vary by region, with Southern and Eastern Europe facing higher burdens. Public health strategies must prioritize effective therapeutic and preventive measures tailored to these geographic disparities.

Dual energy X-ray absorptiometry (DXA) is the recommended reference standard for measuring muscle mass in clinical practice and research due to its balance of feasibility, accuracy, safety, and cost.

If you need to measure your muscle mass accurately, ask for a DXA scan. It is the current best balance of accuracy, safety, and cost. While other methods like BIA scales exist, they are less accurate for individuals. CT and MRI are too expensive and expose you to more radiation (CT) or are less available.

Adipose tissue expansion is dependent on angiogenesis; therefore, inhibiting angiogenesis prevents or reverses obesity by causing adipocyte apoptosis and reducing fat mass.

Fat tissue needs blood vessels to grow. If you stop the growth of new blood vessels, you stop the expansion of fat tissue. This is why antiangiogenic drugs can shrink fat.

Industry-funded studies often report null findings regarding the adverse effects of sugar, potentially due to methodological limitations such as the use of milk as a vehicle, suboptimal statistical analysis, and lack of objective compliance monitoring.

Be skeptical of studies on sugar funded by the sugar industry. Look for independent research with robust methodologies, such as energy-balanced designs and objective compliance measures, to understand the true effects of sugar.

Urbanization is a primary driver of dietary changes, specifically increasing energy intake from fats and sweeteners, independent of total GNP per capita.

Moving to a city in a low-income country tends to increase fat and sugar intake. Policies should focus on urban food environments to prevent this shift.

A high-fat, Western-style diet (HFD) causes systemic low-grade inflammation through gut dysbiosis, increased intestinal permeability (leaky gut), and subsequent translocation of lipopolysaccharide (LPS) into the bloodstream, which activates the TLR4/NF-κB inflammatory pathway.

Your diet directly shapes your gut bacteria. A diet high in fats, especially saturated and omega-6 fats, can damage your gut lining, allowing toxins (LPS) to enter your blood and trigger chronic inflammation. To protect your gut barrier, focus on reducing processed fats and increasing fiber-rich foods that support beneficial bacteria.

Lipopolysaccharide (LPS) translocation from the gut to the blood (metabolic endotoxemia) is a key driver of systemic inflammation, mediated by the TLR4 receptor, and is directly caused by HFD-induced gut barrier dysfunction.

To reduce systemic inflammation, it is not enough to just eat less; you must also protect your gut lining to prevent bacterial toxins (LPS) from entering your bloodstream and triggering an immune response.

Testosterone replacement therapy in middle-aged and older men significantly increases the risk of elevated hematocrit (>50%) and prostate events compared to placebo.

If you are an older man considering testosterone therapy, expect your blood thickness (hematocrit) and prostate markers (PSA) to rise. You must commit to regular blood tests and prostate exams. The risk of heart attacks or death does not appear to increase significantly, but the risk of thick blood and prostate issues does.

Hyperglycemia in Type 2 Diabetes Mellitus causes endothelial dysfunction and platelet hyperactivity through oxidative stress, AGE formation, and PKC activation, leading to accelerated atherosclerosis.

For T2DM patients, controlling blood sugar is not enough to prevent heart disease. You must address the underlying vascular damage caused by high glucose and insulin resistance. This involves managing oxidative stress and inflammation through medication (like SGLT2 inhibitors or GLP-1 agonists mentioned in the text) and lifestyle changes, not just glucose monitoring.

Inhibition of Acetyl-CoA Carboxylase 2 (ACC2) reduces malonyl-CoA levels, thereby removing inhibition on CPT1, which increases fatty acid oxidation, reduces intracellular lipid accumulation, and improves insulin sensitivity in muscle and liver.

Targeting the ACC2 enzyme to lower malonyl-CoA levels appears to be a highly effective strategy for improving insulin sensitivity and reducing liver fat. By preventing the inhibition of fat transport into mitochondria (via CPT1), the body can burn fat more efficiently, which in turn lowers the toxic lipid byproducts that cause insulin resistance. This suggests that therapies aimed at ACC2 inhibition could treat obesity and type 2 diabetes by restoring the body's ability to burn fat.

Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) reduces de novo fatty acid synthesis and hepatic triglyceride accumulation, but may not sufficiently improve insulin sensitivity or fatty acid oxidation on its own compared to ACC2 inhibition.

Blocking the creation of new fat (via ACC1) reduces liver fat but does not fix insulin resistance or obesity on its own. The body compensates by trying to store fat elsewhere or failing to burn it. Effective treatment requires targeting ACC2 to ensure fat is actually burned, not just not made.

Chronic obesity causes adipose tissue dysfunction through a triad of unresolved inflammation, fibrosis, and impaired angiogenesis, driven by persistent hypoxia and adipocyte death.

Obesity is not just about having too much fat; it is about the fat tissue becoming sick due to lack of oxygen, inflammation, and scarring. Simply losing weight might not fix these underlying tissue issues if the diet and lifestyle don't support healthy tissue remodeling. Focus on strategies that improve metabolic health and reduce inflammation, not just scale weight.

Hypoxia in expanding adipose tissue drives a complex response involving both pro-angiogenic and pro-fibrotic pathways, with HIF-1α playing a dominant pro-fibrotic role in obesity.

Low oxygen levels in fat tissue are a double-edged sword. They try to create new blood vessels, but they also trigger scarring and inflammation. In obesity, the scarring and inflammation often win out, worsening metabolic health.